Session

Understanding the biology of therapeutic response in IBD

ANALYSIS OF THE INTERGENERATIONAL EPIGENETIC CONTRIBUTION AND THE EPIGENETIC CLOCK IN PAEDIATRIC IBD
ANALYSIS OF THE INTERGENERATIONAL EPIGENETIC CONTRIBUTION AND THE EPIGENETIC CLOCK IN PAEDIATRIC IBD

EARLY MOLECULAR SIGNATURES OF THERAPEUTIC RESPONSE TO VEDOLIZUMAB THERAPY IN INFLAMMATORY BOWEL DISEASE PATIENTS IDENTIFIED USING A LONGITUDINAL MULTI-OMICS APPROACH
EARLY MOLECULAR SIGNATURES OF THERAPEUTIC RESPONSE TO VEDOLIZUMAB THERAPY IN INFLAMMATORY BOWEL DISEASE PATIENTS IDENTIFIED USING A LONGITUDINAL MULTI-OMICS APPROACH

DIFFERENTIAL AND COMBINATORIAL MECHANISM OF ACTION OF GOLIMUMAB AND GUSELKUMAB IN ULCERATIVE COLITIS INDUCTION THERAPY: IL-23 BLOCKADE DRIVES RESTORATION OF NORMAL EPITHELIUM AND MUCOSAL HEALING
DIFFERENTIAL AND COMBINATORIAL MECHANISM OF ACTION OF GOLIMUMAB AND GUSELKUMAB IN ULCERATIVE COLITIS INDUCTION THERAPY: IL-23 BLOCKADE DRIVES RESTORATION OF NORMAL EPITHELIUM AND MUCOSAL HEALING

BASELINE SERUM BIOMARKERS PREDICT CLINICAL EFFICACY AND TISSUE MOLECULAR RESPONSE TO INDUCTION THERAPY WITH RITLECITINIB, AN ORAL JAK3/TEC INHIBITOR, IN ULCERATIVE COLITIS (UC) (PHASE 2B VIBRATO STUDY)
BASELINE SERUM BIOMARKERS PREDICT CLINICAL EFFICACY AND TISSUE MOLECULAR RESPONSE TO INDUCTION THERAPY WITH RITLECITINIB, AN ORAL JAK3/TEC INHIBITOR, IN ULCERATIVE COLITIS (UC) (PHASE 2B VIBRATO STUDY)

JAK INHIBITION IN EX-VIVOHUMAN INTESTINAL MUCOSA ALTERES INFLAMMATORY RESPONSES MORE PROFOUNDLY IN COLON THAN IN ILEUM WHILE DISPLAYING INDIVIDUAL RESPONSES
JAK INHIBITION IN EX-VIVOHUMAN INTESTINAL MUCOSA ALTERES INFLAMMATORY RESPONSES MORE PROFOUNDLY IN COLON THAN IN ILEUM WHILE DISPLAYING INDIVIDUAL RESPONSES

Understanding the biology of therapeutic response in IBD

BASELINE SERUM BIOMARKERS PREDICT CLINICAL EFFICACY AND TISSUE MOLECULAR RESPONSE TO INDUCTION THERAPY WITH RITLECITINIB, AN ORAL JAK3/TEC INHIBITOR, IN ULCERATIVE COLITIS (UC) (PHASE 2B VIBRATO STUDY)
BASELINE SERUM BIOMARKERS PREDICT CLINICAL EFFICACY AND TISSUE MOLECULAR RESPONSE TO INDUCTION THERAPY WITH RITLECITINIB, AN ORAL JAK3/TEC INHIBITOR, IN ULCERATIVE COLITIS (UC) (PHASE 2B VIBRATO STUDY)

Understanding the biology of therapeutic response in IBD  et al.

DIFFERENTIAL AND COMBINATORIAL MECHANISM OF ACTION OF GOLIMUMAB AND GUSELKUMAB IN ULCERATIVE COLITIS INDUCTION THERAPY: IL-23 BLOCKADE DRIVES RESTORATION OF NORMAL EPITHELIUM AND MUCOSAL HEALING
DIFFERENTIAL AND COMBINATORIAL MECHANISM OF ACTION OF GOLIMUMAB AND GUSELKUMAB IN ULCERATIVE COLITIS INDUCTION THERAPY: IL-23 BLOCKADE DRIVES RESTORATION OF NORMAL EPITHELIUM AND MUCOSAL HEALING

Understanding the biology of therapeutic response in IBD  et al.

EARLY MOLECULAR SIGNATURES OF THERAPEUTIC RESPONSE TO VEDOLIZUMAB THERAPY IN INFLAMMATORY BOWEL DISEASE PATIENTS IDENTIFIED USING A LONGITUDINAL MULTI-OMICS APPROACH
EARLY MOLECULAR SIGNATURES OF THERAPEUTIC RESPONSE TO VEDOLIZUMAB THERAPY IN INFLAMMATORY BOWEL DISEASE PATIENTS IDENTIFIED USING A LONGITUDINAL MULTI-OMICS APPROACH

Understanding the biology of therapeutic response in IBD  et al.

ANALYSIS OF THE INTERGENERATIONAL EPIGENETIC CONTRIBUTION AND THE EPIGENETIC CLOCK IN PAEDIATRIC IBD
ANALYSIS OF THE INTERGENERATIONAL EPIGENETIC CONTRIBUTION AND THE EPIGENETIC CLOCK IN PAEDIATRIC IBD

Understanding the biology of therapeutic response in IBD  et al.

Item 1 - 9 / 9
1